Joint Global Coordinator and Joint Bookrunner
Kempen & Co is pleased to announce that it acted as Joint Global Coordinator and Joint Bookrunner in Xbrane’s SEK 380m Capital Increase
Xbrane is a biopharmaceutical company that develops biosimilars based on a proprietary platform. Xbrane’s lead product - Xlucane - a biosimilar candidate to Lucentis®, addresses ophthalmic VEGFa inhibitor market. Marketing authorization and launch of Xlucane is expected for H2 2022. Xlucane is partnered with biosimilar specialist STADA and ophthalmology specialist Bausch+Lomb for commercialization. Xbrane's pre-clinical candidates include Xcimzane - biosimilar to Cimzia currently under development, and Xdivane - a biosimilar to Opdivo. Xbrane's ambition is to initiate one new biosimilar development program annually and become cash-flow positive by late 2023/early 2024
In the last twelve months, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include: